107 related articles for article (PubMed ID: 19129688)
1. JAK2V617F-positive essential thrombocythemia and multiple myeloma with IGH/CCND1 gene translocation coexist, but originate from separate clones.
Kuroda J; Matsumoto Y; Tanaka R; Kurita K; Kobayashi T; Shimizu D; Kimura S; Ashihara E; Horiike S; Shimazaki C; Taniwaki M
Acta Haematol; 2008; 120(3):177-81. PubMed ID: 19129688
[TBL] [Abstract][Full Text] [Related]
2. Differential positioning and close spatial proximity of translocation-prone genes in nonmalignant B-cells from multiple myeloma patients.
Martin LD; Harizanova J; Zhu G; Righolt CH; Belch AR; Mai S; Pilarski LM
Genes Chromosomes Cancer; 2012 Aug; 51(8):727-42. PubMed ID: 22489023
[TBL] [Abstract][Full Text] [Related]
3. Various patterns of IgH deletion identified by FISH using combined IgH and IgH/CCND1 probes in multiple myeloma and chronic lymphocytic leukemia.
Hwang Y; Lee JY; Mun YC; Seong CM; Chung WS; Huh J
Int J Lab Hematol; 2011 Jun; 33(3):299-304. PubMed ID: 21272268
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical analysis identifies two cyclin D1+ subsets of plasma cell myeloma, each associated with favorable survival.
Cook JR; Hsi ED; Worley S; Tubbs RR; Hussein M
Am J Clin Pathol; 2006 Apr; 125(4):615-24. PubMed ID: 16627271
[TBL] [Abstract][Full Text] [Related]
5. Molecular cytogenetic aberrations in patients with multiple myeloma studied by interphase fluorescence in situ hybridization.
Chen L; Li J; Xu W; Qiu H; Zhu Y; Zhang Y; Duan L; Qian S; Lu H
Exp Oncol; 2007 Jun; 29(2):116-20. PubMed ID: 17704743
[TBL] [Abstract][Full Text] [Related]
6. Detection of the t(11;14)(q13;q32) without CCND1/IGH fusion in a case of acute myeloid leukemia.
Tarsitano M; Palmieri S; Ferrara F; Riccardi C; Cavaliere ML; Vicari L
Cancer Genet Cytogenet; 2009 Dec; 195(2):164-7. PubMed ID: 19963117
[TBL] [Abstract][Full Text] [Related]
7. Correlation between losses of IGH or its segments and deletions of 13q14 in t(11;14) (q13;q32) multiple myeloma.
Trakhtenbrot L; Hardan I; Koren-Michowitz M; Oren S; Yshoev G; Rechavi G; Nagler A; Amariglio N
Genes Chromosomes Cancer; 2010 Jan; 49(1):17-27. PubMed ID: 19787791
[TBL] [Abstract][Full Text] [Related]
8. Functional regulation of D-type cyclins by insulin-like growth factor-I and serum in multiple myeloma cells.
Glassford J; Rabin N; Lam EW; Yong KL
Br J Haematol; 2007 Oct; 139(2):243-54. PubMed ID: 17897300
[TBL] [Abstract][Full Text] [Related]
9. [Study on molecular cytogenetic abnormalities in multiple myeloma].
Liu SY; Li JY; Chen LJ; Huang JW; Pan JL; Qiu HR; Shen YF; Xu W; Xue YQ
Zhonghua Xue Ye Xue Za Zhi; 2007 Apr; 28(4):223-6. PubMed ID: 17877196
[TBL] [Abstract][Full Text] [Related]
10. Cyclin D1 overexpression is not a specific grouping marker, but may collaborate with CDC37 in myeloma cells.
Katayama Y; Sakai A; Okikawa Y; Oue N; Asaoku H; Sasaki A; Imanaka F; Tsujimoto T; Takimoto Y; Masuda R; Nakaju N; Otsuki T; Yasui W; Kimura A
Int J Oncol; 2004 Sep; 25(3):579-95. PubMed ID: 15289859
[TBL] [Abstract][Full Text] [Related]
11. Bone marrow trephine biopsy findings in myeloma with small-lymphoid cells and CCND1 translocation.
Abdalla S; May PC; Garimberti E; Naresh KN
Am J Hematol; 2011 Dec; 86(12):1038. PubMed ID: 21898528
[No Abstract] [Full Text] [Related]
12. A potential role for centrosomal deregulation within IgH translocation-positive myeloma.
Maxwell CA; Pilarski LM
Med Hypotheses; 2005; 65(5):915-21. PubMed ID: 16023302
[TBL] [Abstract][Full Text] [Related]
13. Frequent occurrence of CCND1 deregulation in patients with early stages of plasma cell dyscrasia.
Miura K; Iida S; Hanamura I; Kato M; Banno S; Ishida T; Kusumoto S; Takeuchi G; Miwa H; Nitta M; Inagaki H; Eimoto T; Nomura K; Taniwaki M; Ueda R
Cancer Sci; 2003 Apr; 94(4):350-4. PubMed ID: 12824903
[TBL] [Abstract][Full Text] [Related]
14. Analysis of tumor specific immunoglobulin gene rearrangement in peripheral blood B-cells of multiple myeloma patients by a PCR-SSCP method.
Wu S; Wang L; Wang Y; Zhu P; Xie G
Chin Med J (Engl); 1997 Sep; 110(9):682-5. PubMed ID: 9642324
[TBL] [Abstract][Full Text] [Related]
15. [Transition to aggressive phase in a multiple myeloma patient with IgH/CCND1 translocation and diffuse osteosclerotic lesions].
Hatsuse M; Fuchida S; Okano A; Murakami S; Shimazaki C
Rinsho Ketsueki; 2016 Apr; 57(4):483-8. PubMed ID: 27169455
[TBL] [Abstract][Full Text] [Related]
16. Amplification of IGH/CCND1 fusion gene in a primary plasma cell leukemia case.
Ishigaki T; Sasaki K; Watanabe K; Nakamura N; Toyota S; Kobayashi H; Tohda S
Cancer Genet Cytogenet; 2010 Aug; 201(1):62-5. PubMed ID: 20633772
[TBL] [Abstract][Full Text] [Related]
17. Frequency and distribution of trisomy 11 in multiple myeloma patients: relation with overexpression of CCND1 and t(11;14).
Guglielmelli T; Giugliano E; Cappia S; Papotti M; Saglio G
Cancer Genet Cytogenet; 2007 Feb; 173(1):51-6. PubMed ID: 17284370
[TBL] [Abstract][Full Text] [Related]
18. Molecular classification of multiple myeloma: a distinct transcriptional profile characterizes patients expressing CCND1 and negative for 14q32 translocations.
Agnelli L; Bicciato S; Mattioli M; Fabris S; Intini D; Verdelli D; Baldini L; Morabito F; Callea V; Lombardi L; Neri A
J Clin Oncol; 2005 Oct; 23(29):7296-306. PubMed ID: 16129847
[TBL] [Abstract][Full Text] [Related]
19. Bone marrow stromal cell interaction reduces syndecan-1 expression and induces kinomic changes in myeloma cells.
Fuhler GM; Baanstra M; Chesik D; Somasundaram R; Seckinger A; Hose D; Peppelenbosch MP; Bos NA
Exp Cell Res; 2010 Jul; 316(11):1816-28. PubMed ID: 20307537
[TBL] [Abstract][Full Text] [Related]
20. Chromosomal translocation t(11;14) and p53 deletion induced by the CRISPR/Cas9 system in normal B cell-derived iPS cells.
Azami Y; Tsuyama N; Abe Y; Sugai-Takahashi M; Kudo KI; Ota A; Sivasundaram K; Muramatsu M; Shigemura T; Sasatani M; Hashimoto Y; Saji S; Kamiya K; Hanamura I; Ikezoe T; Onodera M; Sakai A
Sci Rep; 2021 Mar; 11(1):5216. PubMed ID: 33664418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
